Eko Health, a cardiopulmonary digital health company, has successfully raised USD 41 million in a Series D funding round. Participating investors included Artis Ventures, Highland Capital Partners, NTTVC, and Questa Capital. This latest round of funding has brought the company's total funding to USD 165 million.
Eko Health intends to use the funds to train its AI algorithms to detect pulmonary conditions such as asthma and pneumonia. The financing will also be used to expand their sales to doctors outside the US.
The company notes that, as of June 2024, Eko Health has sold its AI-integrated stethoscope to over a half million healthcare providers.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.